The Indefinite Delivery Contract (IDC) SPE2D219D0075 was awarded by the Defense Logistics Agency (DLA) to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The contract has a ceiling value of $40,400,530.45 and a period of performance through June 30, 2024.
The contract aims to establish a national supply source for Budesonide Inhalation Suspension in various dosages, to be purchased by the Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs through the DLA and VA prime vendor programs. Exelan, as the prime contractor, will be responsible for manufacturing, distributing, and repackaging the pharmaceutical products to support the healthcare needs of veterans, military personnel, and other federal beneficiaries. The contract is structured as a firm-fixed price, requirements-type contract with a one-year base period and four one-year option periods, allowing for long-term, stable supply arrangements. The solicitation for this contract was conducted as an unrestricted, fully competitive commercial item acquisition with no set-aside designations.
Generated 1/15/25, 9:10 AM